Physician profile
Benjamin Abraham
NPI 1922265099
$2,606.56
in general payments reported to CMS, 2019-2025
26 companies · $614 in 2025
The $614 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $236 · 2020: $149 · 2021: $588 · 2022: $234 · 2023: $337 · 2024: $449 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $670.05 | 2023-2025 | Qutenza |
| Collegium Pharmaceutical, INC. | $291.64 | 2019-2021 | |
| Baxter Healthcare | $270.14 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $192.12 | 2021-2022 | |
| Amgen INC. | $154.23 | 2019-2024 | Evenity, Tezspire, Prolia |
| Grt US Holding, INC. | $133.01 | 2021-2022 | |
| Medtronic USA, INC. | $116.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $108.43 | 2021-2025 | Acthar |
| United Therapeutics Corporation | $90.34 | 2021-2025 | Tyvaso, Tyvaso |
| Teva Pharmaceuticals USA, INC. | $69.57 | 2020-2021 | |
| Lilly USA, LLC | $68.53 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $59.99 | 2024-2025 | Zerbaxa, Dificid |
| Vertos Medical, INC. | $52.35 | 2022 | |
| Biodelivery Sciences International, INC. | $51.09 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $43.42 | 2025 | Rexulti |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $41.90 | 2024-2025 | Opsumit |
| Spr Therapeutics, INC | $30.22 | 2021 | |
| Relievant Medsystems, INC. | $21.69 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $21.65 | 2025 | Imfinzi |
| Mylan Specialty L.P. | $21.23 | 2023 | Yupelri |
| Ani Pharmaceuticals, INC. | $20.69 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $20.40 | 2021 | |
| Hikma Pharmaceuticals USA | $16.53 | 2022 | |
| Inogen, INC. | $16.13 | 2023 | Inogen |
| Vertex Pharmaceuticals Incorporated | $13.13 | 2024 | |
| Almatica Pharma LLC | $12.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.